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Abstract
Background—Nationwide estimates examining Bone Morphogenetic Protein (BMP) use with
cervical spine fusions have been limited to perioperative outcomes.
Purpose—Determined the one-year risk of complications, cervical revision fusions, hospital re-
admissions and healthcare services utilization.
Study Design/Setting—A retrospective cohort study from 2002 to 2009 utilizing a nationwide
claims database.
Patient Sample—There were 61,937 primary cervical spine fusions of which 1,677 received
BMP.
Outcome Measures—Complications, revision fusions, 30-day hospital readmission and
healthcare utilization.
Methods—Data for these analyses come from the Thompson Reuters MarketScan® Commercial
Claims and Encounters Database © 2010. Patients were aged 18 to 64 receiving and not receiving
BMP with a primary (C2–C7) cervical spine fusion. All outcomes were defined by ICD-9 and
CPT codes. Complications were analyzed as any complication and stratified by nervous system,
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wound, and dysphagia or hoarseness. Cervical revision fusions were determined in the one-year
follow-up. Hospital re-admission discharge records defined thirty-day hospital re-admission and
reason for re-admission. The utilization of at least one healthcare service of cervical spine
imaging, epidural usage or rehabilitation service was examined. Poisson regression models were
used to estimate the relative risk (RR) and 95% confidence intervals (CI). Linear regression was
used to determine time to hospital re-admission. Results were stratified by anterior or posterior
and circumferential approach.
Results—Patients receiving BMP were 29% more likely to have a complication (adjusted
relative risk [aRR]=1.29 ((95% CI 1.14 to 1.46)) and nervous system complication (aRR=1.42
((95% CI 1.10 to 1.83)). Cervical revision fusions were more likely among patients receiving
BMP (aRR=1.69 ((95% CI 1.35 to 2.13)). The risk of 30-day re-admission was greater with BMP
use (aRR=1.37 ((95% CI 1.07 to 1.73)), and re-admission occurred on average 27.4% sooner.
Patients receiving BMP were more likely to receive computed tomography scans (aRR=1.34
((95% CI 1.06 to 1.70)) and epidurals with anterior surgical approaches (aRR=1.29 ((95% CI 1.00
to 1.65)).
Conclusions—These findings question both the safety and effectiveness of off-label BMP use
in primary cervical spine fusions.
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An estimated 1.3 million cervical procedures were performed in the US between 2002 and
2009, with a significant increasing trend of procedures across these years.1 These procedures
have been accompanied by a shorter length of hospital stays (LOS) and increasing number
of procedures on patients with comorbidities.2 National estimates indicate that 3.9% of
patients will have a complication following cervical spine fusion with this estimate
becoming higher with increasing patient age and among posterior or circumferential
approaches.3 Hospital re-admission related to cervical spine fusion complications are not
uncommon (7.9%)4 and re-operation rates have been estimated to be 2.5% per year
following initial cervical spine surgery.5
Bone morphogenetic protein (BMP) is a novel technology designed to stimulate bone
growth and increase the likelihood of bony fusion.6 This could be especially meaningful for
patients who are at risk of nonunion following spine fusion.7 Approved by the Food and
Drug Administration (FDA) in 2002, for limited use in the lumbar spine8, BMP use has been
off-label in the cervical spine9, thoracic spine9 and during pediatric spinal arthrodesis10. In
2006, national estimates indicated that BMP was used in 25% of all spinal fusions with a
high rate of complication occurrence.9 In addition, over the past few years the safety of
BMP use has raised concerns with conflicting study results and questionable omission of
related complications in prior publications.11
Nationwide estimates of complications related to BMP use with cervical spine fusion have
been primarily perioperative; limiting the understanding of the effects that BMP exposure
has following index hospital discharge. In the lumbar spine, within a one-year period, BMP
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use has been associated with a decrease in revision fusions procedures12 and complication
rates related to BMP use have been much lower than those found in the cervical spine.9,13
We are unaware of any national level data specifically determining revision fusions in the
cervical spine among those receiving BMP during a primary cervical spine fusion. 30-day
hospital re-admissions have been reported to be significantly greater among Medicare
beneficiaries receiving BMP during cervical spine fusion.4 Whether this is true in a younger
population has not been investigated on a national level. To fill these gaps in the literature,
we analyzed a large nationwide U.S claims database to examine patients aged 18–64 with
one-year continuous insurance enrollment, receiving and not receiving BMP, during a
primary cervical spine fusion to determine: 1) the one-year risk of complications and
revision fusion surgery 2) differences in 30-day re-admission rates, and 3) differences in the
utilization of rehabilitation services, imaging, or epidural pain management. We
hypothesized that the use of BMP would increase rates of complications and subsequent
revision fusion, result in higher hospital re-admission rates, and a greater proportion of
healthcare services utilized over a one-year period.
Methods
Data for these analyses come from the Thompson Reuters MarketScan® Commercial
Claims and Encounters Database © 2010 administered by Truven Health Analytics
(formerly Thomson Reuters Inc., New York, NY). These data are deidentified U.S health
insurance claims including both inpatient and outpatient settings. Over 100 different
insurance companies nationwide and large employers contribute to the database, with some
portions of the US, such as the South represented more than the Northeast. These include
fee-for-service, preferred provider organizations, and capitated health plans.14 This database
has been used to establish national estimates related to surgical outcomes15,16 as well as
outcomes related to BMP use in the lumbar spine12. Data were collected from the database
utilizing International Classification of Diseases, 9th edition Clinical Modification (ICD-9)
and/or Current Procedural and Terminology, 4th edition (CPT).
Patients >=18–64 years of age and undergoing a primary cervical spine (C2–C7) fusion
(n=94,364) were eligible. Cervical fusions were classified by anterior (ICD-9: 81.02 or CPT:
22554), posterior (ICD-9: 81.03 or CPT: 22600), or circumferential (both anterior and
posterior approaches on the same date) from 2002 (the first year of FDA approved BMP
use) to year 2009 (last available year which meets our inclusion criteria). Only patients with
one-year of continuous health insurance enrollment from the date of fusion were eligible
(n=64,283). Patients with trauma, spine infection and spine cancer were excluded (n=2,346).
Atlas-axis (C1–C2) fusions were not included, as the ICD-9 coding does not distinguish
between surgical approaches (i.e., anterior or posterior).
The primary exposure was BMP (ICD-9: 84.52). The proportion of BMP use and overall
cervical spine fusions were examined by study year. Covariates at the time of index surgery
included; Metropolitan Statistical Area (MSA) of the beneficiary (categorized as a urban/
unknown or rural region), age (continuous), gender, insurance type categorized as capitated
(no dollar amount is set to cover costs) or non-capitated (a fixed dollar amount is set to
cover costs) and unknown insurance type, number of levels fused (categorized as 2–3
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(ICD-9: 81.62 and CPT: 22845 and 22842) or 4+ levels (ICD-9: 81.63 and CPT: 22846 and
22843) and primary admission diagnosis (categorized similar to Cahill and colleagues9 as
either disk herniation or degenerative disease [ICD-9: 722.0–722.8, 722.9, 724.0, 723.7,
721, 738.4]or other diagnoses). The Elixhauser Comorbidity Index17,18 was used to identify
comorbidities from both inpatient and outpatient claims in the 3 months prior to and on date
of the index surgery. Comorbidities were categorized by the number of comorbidities per
patient as 0–3+ (few patients had greater than 3 comorbidities). Hospital region was
database defined as South, West, Northeast and North Central.
Complications were classified similar to Cahill et al.9 by ICD-9 coding. Any surgical or
medical complication (996.0–999.0), medical complications included myocardial infarction,
shock, deep vein thrombosis, pneumonia and pulmonary embolus (997.1, 410.0–410.9,
998.0, 997.3, 415.1, 997.2). Nervous system complications included stroke, hemorrhage and
other nervous system complications (997.0–997.9). Wound related complications included
infection, dehiscence, seroma and hematoma (998.1, 998.11, 998.12, 998.13, 998.3, 998.31,
998.32, 998.83, 998.5, 999.3, 998.51, 998.59). Complications related to dysphagia/
hoarseness (478.30, 478.31, 478.32, 478.33, 478.34, 784.4, 787.2). Multiple complications
in the same classification were not included and categories of complication are not mutually
exclusive. Cervical revision fusion surgeries in the one-year period following index surgery
were identified by anterior and posterior approaches (82.32 and 82.33).
Thirty-day re-admissions were defined as a hospital admission within 30 days of index
surgery discharge. Time, in days, was measured from the date of discharge to the date of re-
admission. Common reasons for re-admission were determined from primary ICD-9
diagnosis coding.
The utilization of rehabilitation services (physical therapy [CPT: 97001, 97002, 97110,
97140, 97124, 97150], speech therapy [CPT: 92610 and 92611] and occupational therapy
[ICD-9: 93.83 and CPT: 97003 and 97004]), spine imaging (cervical spine magnetic
resonance imaging [ICD-9: 88.93 and 88.97 and CPT: 72141 and 72156] cervical spine CT
scans [ICD-9: 87.03 and CPT: 72125, 72127, 72126], cervical spine plain film radiographs
[ICD-9: 87.21–87.29 and CPT: 72040, 72050 and 72052], cervical myelogram [ICD-9:
87.21 and CPT: 72240 and 72126]), and cervical/thoracic epidurals (CPT: 62310 and 62318)
were identified from claims in the one-year following the index surgery date.
Statistical Analysis
Counts with proportions and medians with interquartile range were used to describe
univariate distributions. Since some of our outcomes were not rare (i.e., >10% incidence),
Poisson regression was used to model the relative risk (RR) and 95% confidence intervals
(CI) of complications, revision fusions, re-admissions and healthcare utilization,
accompanied by a robust variance estimator.19 Pearson chi-square p-values indicated an
excellent fit for all models with p-values >0.99. Days to re-admission were logarithmic
transformed to account for the positive skew of data (i.e., most re-admissions were not
immediate and data were not normally distributed) and modeled with linear regression.
Transformed coefficients represent the geometric mean or average time to hospital re-
admission. Results were stratified by anterior surgical approach, however due to the
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relatively small sample, posterior and circumferential approaches were combined in separate
strata. We explored whether there were differences between the risk of any complication or
hospital re-admission before and after the peak use of BMP in our data with an interaction
term between year of BMP use and study year dichotomized at <2006 vs. >=2006. Unknown
values for the levels of fused vertebrae were imputed according to Rubin’s rules20 with 50
imputations in each multivariable model. Diagnostics from imputation models indicated no
gross differences between the observed and imputed values and reasonable completed
distributions. All regression models were adjusted for age, gender, MSA of the beneficiary,
imputed levels of fusion, insurance type, hospital region, admission diagnosis, comorbidities
and study year. Chi square tests were used for differences in proportions. Alpha was set at
p<0.05, all analyses were un-weighted and performed in Stata 12.0 (Stata Corp, College
Station, Tx).
We conducted several simple sensitivity analyses. We examined our results with and
without imputed data for levels of cervical spine fusion (Appendix table 1) and found no
appreciable differences in the strength of the estimates (i.e., <5% change in estimates). We
decided to maintain the imputation models for these analyses since the imputed estimates
were more precise as there was as there was a large amount of missing data for this
important variable (10%) and this variable was strongly associated with BMP use. The
propensity for BMP use was examined with matched models (Coarsened Exact Matching21).
No appreciable differences (<10% change in estimate) were found between adjusted and
matched models with our major outcomes nor were there changes in statistical significance.
A majority of the estimates from unmatched models were more conservative or did not
differ in strength of the estimate (i.e., calculated as a the change in the natural log of the
estimates) when compared to the matched models with the exception of revision fusions
(Appendix table 2). We report the adjusted models due to the loss of data that can occur
from a lack of matching, especially with a rare exposure, which limited our ability to
perform stratified analysis by surgical approach. Finally, we determined if there were
differences in the distribution of BMP and covariates among those patients meeting and not
meeting our enrollment eligibility (see Appendix tables 3 and 4). These findings indicate
those meeting and not meeting the one-year eligibility requirements are similar in BMP
distribution, demographic and clinical characteristics, however patients not meeting one-
year enrollment eligibility had a higher proportion of comorbidities.
Results
These analyses consist of 61,937 patients with one-year continuous insurance enrollment
following a primary (C2–C7) cervical spine fusion. The majority of fusions utilized an
anterior approach (92.8%, n=57,484) with a smaller proportion of posterior (5.2%, n=3,209)
and circumferential (2.0%, n=1,244) approaches. The use of BMP rose from 0.24% in the
year 2002 to peak (4.8%) in the year 2007 and declined to 2.0% in 2009. The proportion of
overall primary cervical spine fusions increased to 11,561 cervical fusions performed in
2008 (18.7% of the total sample). (Figure 1)
Table 1 describes both individual patient and hospital level characteristics by BMP status.
The use of BMP was similar across age, gender, and beneficiary MSA. BMP use was
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strongly associated with posterior (relative risk [RR]=1.67 ((95% CI 1.41 to 1.98)) and
circumferential approaches (RR=1.87 ((95% CI 1.46 to 2.41)), and 4+ levels fused
(RR=1.96 ((1.76 to 2.18)). The use of BMP was strongly and independently related to the
number of comorbidities, with increasing use of BMP with increasing comorbidities
(p<0.001 for differences in comorbidity categories).
Table 2 presents the events, unadjusted and adjusted RRs with 95% CIs for complications in
a one-year period by BMP status. Patients receiving BMP, with any approach, were 29%
more likely to have any complication in a one-year period (adjusted relative risk [aRR]=1.29
((95% CI 1.14 to 1.46)) that was similar for anterior approaches but stronger for posterior/
circumferential approaches. There was a strong risk of nervous system complication
(aRR=1.42 ((95% CI 1.10 to 1.83)) that was similar for anterior approaches and posterior/
circumferential approaches. A high risk for revision fusion surgery in a one-year period with
BMP use (aRR=1.69 ((95% CI 1.35 to 2.13)) and similar for anterior approaches and
posterior/circumferential approaches.
The years when BMP was used significantly modified the risk of any complication. Prior to
the year 2006, there was a high risk of any complication (aRR=1.60 ((95% CI 1.30 to 1.97)),
whereas in 2006 and after, this risk decreased (aRR=1.21 ((95% CI 1.08 to 1.37)) but
remained significant (ratio of aRR=1.32 ((95% CI 1.04 to 1.67)).
Table 3 presents the risk of 30-day admission following index hospitalization discharge and
days to that re-admission. Of the 61,383 fusions discharged (excluding death [n=5],
rehabilitation admission [n=471] and >30 day LOS [n=78]), 2.7% (n=1,643) had a 30-day
hospital re-admission. Patients receiving BMP had a 34% increased risk of 30-day re-
admission (aRR=1.34 ((95% CI 1.06 to 1.70)) and a similar risk for anterior approaches
(aRR=1.33 ((95% CI 1.01 to 1.75)). Common reasons for re-admission by patients receiving
BMP versus not receiving BMP were: wounds (25.7% vs. 17.7%, p=0.08), spondylosis or
intervertebral disc related (18.9% vs. 19.0%, p=0.99), medical complication (13.0% vs.
10.0%, p=0.35), and dysphagia or edema of the larynx (9.5% vs. 3.3%, p<0.01). Re-
admission on average was 27.4% sooner among patients receiving BMP (−27.4% ((95% CI
−38.9% to − 13.6%)). No significant interaction (p=0.36) between year and BMP use was
found with 30-day re-admission.
Table 4 presents the utilization of rehabilitation services, imaging, and epidurals in the year
following index surgery. Regardless of fusion approach, patients receiving BMP were 30%
more likely to have cervical spine CT scans (aRR=1.30 ((95% CI 1.18 to 1.43)). These
results were similar with anterior approaches. Epidural/block use was significantly higher
(aRR=1.29 ((95% CI 1.00 to 1.65)) among patients receiving BMP with an anterior
approach. Epidural use (12.5% vs. 5.2%, p<0.001) and CT scans (40.3% vs. 24.3%,
p<0.001) were more common among patients having a revision fusion if they received BMP
during a primary cervical fusion.
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The use of BMP during cervical spine fusions has received considerable attention over the
past several years. This in part due to the high number and severity of complications with
BMP use that has been alarming and warrants intense scrutiny.22 Adverse events attributed
to BMP use were relatively rarely reported in the early experience. Early clinical trials
determining the efficacy of BMP noted no adverse events in the cervical spine.23,24
However, clinical trials are not typically statistically powered to determine these
differences.25 Moreover, some have indicated that adverse events related to BMP may be
underestimated11 and possibly not known26. Although certainly not without limitation, this
makes observational studies incredibly important for understanding rare outcomes such as
this. Across most all of our complication outcomes there was a noticeable increased risk of
complication associated with the use of BMP. This was especially true of the one-year risk
of any complication following a primary cervical spine fusion despite the surgical approach
utilized. The ICD9 codes utilized for these complications represent a broad range of medical
and surgical complications and provide a larger scale view of complications related to BMP
use, some of which may be more likely to occur following index hospitalization that may
have not been captured in previous perioperative studies.
Our analyses revealed that patients receiving BMP were at increased risk of nervous system
complications. This contrasts a previous study, which reported no delayed neurological
deficits, associated with BMP use, however these findings are reported for BMP use among
lumbar, thoracic and cervical fusions combined.27 Reasons related to neurological
complication found in our study might be related to ectopic bone in the spinal canal,
reported by Wong et al.28, which may contribute to neurologic compromise. A similar risk
was found with posterior/circumferential approaches although the substantially smaller
sample size in this subgroup is the likely reason for the decreased statistical power and
imprecision found for this estimate. This may also be the case with medical complications.
The strength of our estimates indicated a high risk of medical complication whereas the rare
number of occurrences resulted in limited statistical power, which should be taken into
consideration when determining benefit versus safety.
Our results regarding dysphagia/hoarseness contrast several previous studies and
reviews.9,22,27,29,30 Differences in patient characteristics may be one explanation for this
finding. Williams and colleagues27 report a significant risk of wound infections associated
with anterior cervical approaches. However, their analyses were not adjusted for many of the
covariates we which we found to be strong confounders (i.e., insurance, levels of fusion and
comorbidities). Cahill and colleagues9 also reported increased associated wound infection
with BMP use in data from the National Inpatient Sample. Patient age and related
comorbidities may be one reason for the differences between our study results, as our
sample was substantially younger due to the absence of Medicare claims. According to
traditional statistical criteria our results for dysphagia/hoarseness among anterior cervical
fusions are not significant, however this borderline significance should be considered when
making judgments based upon patient safety.
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We found a 32% greater risk of any complication with BMP use prior to the year 2006.
Some have reported that complications with BMP use have been intimately related to the
dosage of BMP.22,31 This may be one reason for this significant decrease in the risk of
complication observed in these analyses as these reports occurred near the year examined for
this interaction effect. Despite the decline in risk after 2006, patients receiving BMP
continued to have a significant risk of any complication. With claims data we are unable to
determine the dosage and location of BMP used during these years and surgeon level
practices that could greatly influence these estimates.
We determined the risk of cervical revision fusion surgery following BMP use within a one-
year period; a period of time with which the therapeutic effects of BMP use would be
expected. Our work regarding revision contrasts several previous studies finding a high
fusion rate in the cervical spine23,32–36 whereas others have found excessive bone growth,
cyst formation and osteolysis37. The differences in sample size and methodologies between
our study and these others make comparisons difficult. Our results regarding revision fusion
should be interpreted with caution since we are unable to accurately determine if the
revision fusion was of the primary cervical fusion in that same year. However, surgeons are
typically less likely to conduct a revision fusion in the same year without necessity.
Moreover, within our data (results not shown) a majority of those patients receiving BMP
and requiring a revision fusion surgery also had a complication during that year. This link
between complication, BMP use and revision surgery or other invasive intervention has also
been found in reports to the FDA.26
General interest in hospital re-admission has increased in recent years.38 Similar to a recent
study by Wang and colleagues4, Medicare patients receiving BMP had an increased risk of
hospital re-admission. Several reasons for re-admission were identified in these analyses and
could be considered modifiable complications. Dysphagia and larynx edema is one such
complication that has been linked to BMP use and is considered a serious adverse event
needing emergency medical intervention.39 Previous studies examining re-admission
complications related to dysphagia and larynx edema have been case reports or small
samples with limited generalizability.29,40 Our findings indicate this is a significant reason
for 30-day re-admission related to BMP use. The median time to re-admission in our study
also coincides with times when a serious adverse event such as this is likely to occur (i.e., 7–
14 days).39
We found a greater utilization of imaging and epidural pain management among patients
receiving BMP. Patients receiving BMP during primary fusion had increased use of CT
scans with either anterior or posterior/circumferential and epidural use among anterior
approaches. The increased use of CT scans and epidural use may be related to complications
influencing bony union and continued symptoms among these patients, as a higher
proportion of these patients had a revision fusion in the one-year period.
Our study is not without limitations. These results may not be generalizable to an older
population, as Medicare claims were not included. However, the known differences between
complications, comorbidities and re-admissions may preclude pooling age groups into a
single estimate. The absence of Medicare claims data, is likely a large reason why our
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estimates of cervical procedures, BMP use and complication rates are lower than previous
published nationwide estimates. We also had a substantial number (34%) of patients who
were not eligible due to our enrollment criteria. Our sensitivity analysis did not reveal any
substantial reasons between those included and not included with the exception of
comorbidities. With claims data there is the possibility of miscoding, resulting in
misclassification of the exposure or outcomes. We do not feel that there are any specific
reasons why this would be differential by BMP status. These analyses are of observational
data and not experimental. We adjusted for confounding factors that have been found in
previous studies. The majority of difference in unadjusted and adjusted estimates was due to
the presence of comorbidities and levels of fusion. For our major outcomes, the effect was
consistently and significantly greater than the null (i.e., RR above 1.0). While residual
confounding is certainly possible, it is unlikely that this would result in a statistically
significant or clinically important effect from the administration of BMP since our
sensitivity analysis indicated that most of the matched models, which theoretically would
adjust for confounding by indication, were not significantly different from unmatched
models. Lastly, despite our large sample size we were unable to stratify our regression
models with some important findings (e.g., nervous system complications) by ICD-9
diagnostic codes to better understand the clinical implications of this particular diagnosis
and BMP use.
We find consistent evidence of complications with BMP use in primary cervical spine fusion
within a one-year period, a period of time that has not been examined in previous reports. In
contrast to the lumbar spine, BMP use during cervical spine fusion was not associated with a
decrease in revision fusion surgery procedures. The use of BMP during primary cervical
spine surgery resulted in a higher hospital re-admission rate and increased healthcare
utilization. Results from these analyses question both the safety and effectiveness in the off-
label use of BMP for primary cervical spine fusions. Our findings, however, represent the
past several years and recent evidence has improved our understanding of the safety of BMP
use. In our data, the use of BMP during primary cervical spine fusions appears to be
declining. This may be due to the recognized complications associated with BMP use, as
complications are so prevalent with anterior cervical spine procedures that many surgeons
no longer use BMP in this area.41 Efforts to create a guideline driven approach to the
utilization of BMP are ongoing25 and greatly needed in order to better inform clinicians and
prevent undue harm to patients.
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Proportion of primary cervical spine fusions and use of BMP from 2002–2009 (n=61,937).
Diamonds represent the proportion of BMP use and squares represent the overall proportion
of cervical spine fusions.
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Table 1
Characteristics of patients and hospitals receiving or not receiving bone morphogenetic protein (BMP) during
primary cervical spine fusion from 2002–2009
Characteristic No BMP (n=60,260) BMP (n=1,677) BMP use relative risk (95% CI)
Age, mean (SD) 49.7 (8.1) 50.0 (8.1) 1.00 (1.00 to 1.01)
Sex, n (%)
 Men 27,339 (45.4) 731 (43.6) ref
 Women 32,921 (54.6) 946 (56.4) 0.93 (0.85 to 1.03)
Insurance Type, n (%)
 Capitated or Unknown 10,390 (17.2) 245 (14.6) ref
 Non-Capitated 49,870 (82.8) 1,432 (85.4) 1.21 (1.06 to 1.39)
MSA, n (%)
 MSA 47,467 (78.8) 1,306 (77.9) ref
 Non-MSA or Unknown 12,793 (21.3) 371 (22.1) 1.03 (0.93 to 1.15)
Fusion Approach, n (%)
 Anterior 56,005 (92.9) 1,479 (88.2) ref
 Posterior 3,071 (5.1) 138 (8.2) 1.67 (1.41 to 1.98)
 Circumferential 1,184 (2.0) 60 (3.6) 1.87 (1.46 to 2.41)
Vertebral Levels Fused, n (%)
 2–3 46,690 (77.5) 1,257 (75.0) ref
 >=4 7,483 (12.4) 405 (24.2) 1.96 (1.76 to 2.18)
 Unknown 6,087 (10.1) 15 (0.9) N/A
Number of Comorbidities*, n (%)
 0 33,316 (55.3) 687 (41.0) ref
 1 18,073 (30.0) 530 (31.6) 1.41 (1.26 to 1.58)
 2 6,228 (10.3) 295 (17.6) 2.24 (1.96 to 2.56)
 3+ 2,643 (4.4) 165 (9.8) 2.91 (2.47 to 3.43)
Diagnosis, n (%)
 disk herniation or degenerative disease 45,655 (75.8) 1,229 (73.3) ref
 Other conditions 14,605 (24.2) 448 (26.7) 1.14 (1.02 to 1.26)
Hospital Region, n (%)
 South 32,730 (54.3) 871 (51.9) ref
 North Central 14,962 (24.8) 405 (24.2) 1.02 (0.91 to 1.14)
 West 8,538 (14.2) 373 (22.2) 1.61 (1.43 to 1.82)
 Northeast or Unknown 4,030 (6.7) 28 (1.7) 0.26 (0.18 to 0.39)
MSA=metropolitan statistical area of beneficiary, ref=referent category,
*
Comorbidities from the Elixhauser Comorbidity Index.
BMP use estimated with Poisson regression
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